429 related articles for article (PubMed ID: 18996386)
1. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
Villet S; Billioud G; Pichoud C; Lucifora J; Hantz O; Sureau C; Dény P; Zoulim F
Gastroenterology; 2009 Jan; 136(1):168-176.e2. PubMed ID: 18996386
[TBL] [Abstract][Full Text] [Related]
2. Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants.
Billioud G; Pichoud C; Parent R; Zoulim F
J Hepatol; 2012 Jun; 56(6):1269-75. PubMed ID: 22314422
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus mutations associated with antiviral therapy.
Bartholomeusz A; Locarnini S
J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity.
Blanchet M; Sureau C
J Virol; 2006 Dec; 80(24):11935-45. PubMed ID: 17020942
[TBL] [Abstract][Full Text] [Related]
5. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion.
Vietheer PT; Netter HJ; Sozzi T; Bartholomeusz A
J Virol; 2005 May; 79(10):6570-3. PubMed ID: 15858045
[TBL] [Abstract][Full Text] [Related]
6. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus genetic diversity.
Echevarría JM; Avellón A
J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
[TBL] [Abstract][Full Text] [Related]
9. Evolution of multi-drug resistant hepatitis B virus during sequential therapy.
Yim HJ; Hussain M; Liu Y; Wong SN; Fung SK; Lok AS
Hepatology; 2006 Sep; 44(3):703-12. PubMed ID: 16941700
[TBL] [Abstract][Full Text] [Related]
10. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
[TBL] [Abstract][Full Text] [Related]
11. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
Zoulim F
Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
[TBL] [Abstract][Full Text] [Related]
13. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity.
Gripon P; Le Seyec J; Rumin S; Guguen-Guillouzo C
Virology; 1995 Nov; 213(2):292-9. PubMed ID: 7491754
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus escape mutants induced by antiviral therapy.
Sheldon J; Soriano V
J Antimicrob Chemother; 2008 Apr; 61(4):766-8. PubMed ID: 18218641
[TBL] [Abstract][Full Text] [Related]
15. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
16. [Construction of whole-genome lamivudine-resistant hepatitis B virus mutant and its replication and expression in HepG2 cells].
Sun J; Wang C; Wen SJ; Wang ZH; Hou JL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):991-3. PubMed ID: 17666334
[TBL] [Abstract][Full Text] [Related]
17. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
Lai MW; Yeh CT
Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
[TBL] [Abstract][Full Text] [Related]
19. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
Locarnini S; Warner N
Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
[TBL] [Abstract][Full Text] [Related]
20. High replicative full-length lamivudine-resistant hepatitis B virus isolated during acute exacerbations.
Zhang JM; Yao X; Wang YX; Liu F; Ma ZM; Weng XH; Wen YM
J Med Virol; 2005 Oct; 77(2):203-8. PubMed ID: 16121368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
